Theranostic Newsletter | 07.2025 Edition

Here’s your latest dose of Theranostic Insights—a curated snapshot of what’s new and next in the world of theranostics powered by TheranosticTrials.org. From clinical breakthroughs to tech trends, we’ve got the highlights you need to stay ahead.

Latest Theranostic News 📰

Mayo Clinic Launches First U.S. Theranostic Treatment for Breast Cancer Using Alpha-Emitter

Mayo Clinic has become the first U.S. center to treat a patient with a novel theranostic radiopharmaceutical therapy for advanced breast cancer, using actinium-225 to deliver highly targeted alpha radiation. This next-generation treatment, developed by RayzeBio Inc., a Bristol Myers Squibb company, offers potent precision by destroying cancer cells while sparing healthy tissue. The therapy is part of a phase 1b/2 international clinical trial and could mark a major advance for patients with ER+ metastatic breast cancer.
Continue reading here.

Radioimmunotherapy Breakthrough Targets Ovarian Cancer Stem Cells

A novel theranostic approach using Terbium-161 (161Tb) radioimmunotherapy has shown unprecedented success in eradicating cancer stem cells (CSCs) in preclinical ovarian cancer models. Researchers at the Paul Scherrer Institute demonstrated that 161Tb-DOTA-chCE7 significantly outperforms the current standard Lutetium-177 (177Lu) by eliminating both CSCs and their differentiated tumor cells, paving the way for more effective, personalized radionuclide therapies. This marks a critical advancement in theranostics, offering new hope for overcoming tumor relapse and therapy resistance. Continue reading here.

Targeted Radiotherapy Shows Promise for Glioblastoma with Lutetium-177 ITM-31

Lutetium-177 ITM-31 (177Lu-LuCaFab) is a novel theranostic therapy designed to target glioblastoma by homing in on carbonic anhydrase XII (CAXII), a protein present on tumor cells but absent in healthy brain tissue. Administered directly into the surgical cavity after tumor resection, this precision radioimmunotherapy aims to eliminate residual cancer cells and prevent recurrence. Currently in Phase I trials, it represents a major advance in the localized, targeted treatment of glioblastoma and underscores the expanding role of theranostics in neuro-oncology. Continue reading here.

STARLiT Trial Explores ADT-Free Theranostic Strategy for Prostate Cancer

The STARLiT trial, presented at SNMMI 2025, is testing a novel theranostic approach that combines stereotactic body radiotherapy (SBRT) with 177Lu-PSMA-617 for patients with very high-risk, locally advanced prostate cancer. This strategy aims to avoid androgen deprivation therapy (ADT) and its associated long-term toxicities, especially important for patients with pre-existing cardiovascular risk. With a focus on ADT-free survival, treatment tolerability, and quality of life, STARLiT could redefine the standard of care using dual cytotoxic, non-hormonal therapies. Continue reading here.